8-K: Adaptive Biotechnologies Reports Strong Q3 2025 Results

Adaptive Biotechnologies reported robust third quarter 2025 financial results, driven by significant growth and profitability in its MRD business segment.

Summary

• Revenue for the third quarter of 2025 was $94.0 million, a 102% increase from the third quarter of 2024.
• Excluding revenue from the terminated Genentech Agreement, Q3 2025 revenue was $60.2 million, representing a 40% increase year-over-year.
• The Minimal Residual Disease (MRD) business contributed 60% of total revenue, growing 52% to $56.8 million versus Q3 2024.
• The MRD business achieved cash flow positivity and profitability with Adjusted EBITDA of $7.0 million in Q3 2025.
• clonoSEQ test volume increased 38% to 27,111 tests delivered in Q3 2025 compared to Q3 2024.
• Net income for Q3 2025 was $9.5 million, a significant improvement from a net loss of $32.1 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $28.0 million, compared to a loss of $14.3 million in Q3 2024.
• Full year 2025 MRD revenue guidance was raised to a new range of $202 million to $207 million, implying annual growth of 39% to 42%.
• Full year 2025 total company operating expenses guidance was reduced to $335 million to $340 million.
• Full year 2025 total company cash burn guidance was reduced to $45 million to $50 million.
• Cash, cash equivalents, and marketable securities stood at $216.8 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company reported strong financial results, particularly in its MRD segment, achieving profitability and cash flow positivity. Raised revenue guidance and reduced expense/cash burn guidance indicate positive operational momentum and financial discipline. The termination of the Genentech agreement is a minor negative, but overall performance is very positive.

Positives

• Total revenue increased by 102% year-over-year to $94.0 million in Q3 2025.
• MRD business revenue grew 52% year-over-year to $56.8 million, demonstrating strong market adoption.
• The MRD business achieved both profitability and cash flow positivity in Q3 2025, with an Adjusted EBITDA of $7.0 million.
• clonoSEQ test volume saw a substantial 38% increase to 27,111 tests delivered.
• NCCN guidelines were updated in CLL to incorporate MRD-guided treatment duration, which is expected to further drive clonoSEQ adoption.
• Recognized $6.5 million in MRD pharma regulatory milestone revenue.
• Full year 2025 MRD revenue guidance was raised to $202 million $207 million, indicating strong future expectations.
• Full year 2025 total company operating spend and annual cash burn guidance were reduced, reflecting improved cost management and financial discipline.
• Achieved a net income of $9.5 million in Q3 2025, a significant turnaround from a net loss of $32.1 million in the prior year.

Negatives

• The Genentech Agreement was terminated in August 2025, which led to a one-time revenue recognition of $33.7 million but will impact future Immune Medicine revenue.
• Interest and other income, net, decreased to $2.2 million in Q3 2025 from $3.5 million in Q3 2024.
• Excluding revenue from the Genentech Agreement, the company still reported a net loss of $24.2 million for Q3 2025.
• Excluding revenue from the Genentech Agreement, Adjusted EBITDA was a loss of $5.8 million for Q3 2025.

Risks

• Ability to develop, commercialize, and achieve market acceptance of current and planned products and services.
• Uncertainties related to research and development efforts.
• Forward-looking statements are based on a combination of facts and factors currently known and projections of the future, about which certainty cannot be guaranteed, potentially leading to actual results differing materially.

Future Outlook

Management raised full year 2025 MRD revenue guidance to a new range of $202 million to $207 million, implying annual growth of 39% to 42%. They also reduced the total company full year 2025 range for operating spend to $335 million to $340 million and annual cash burn to $45 million to $50 million, reflecting disciplined execution and strong momentum. Further details on the outlook will be provided during the conference call.

Management Comments

• "Our third quarter results reflect another period of strong growth and financial progress." Chad Robins, chief executive officer and co-founder.
• "Our MRD business has reached a major inflection point, having achieved both profitability and cash flow positivity, driven by disciplined execution and accelerating adoption of clonoSEQ." Chad Robins, chief executive officer and co-founder.
• "With strong momentum in MRD and good progress in our Immune Medicine programs, we're well positioned for sustained growth and long-term value creation." Chad Robins, chief executive officer and co-founder.

Industry Context

The company operates in the biotechnology sector, specifically focusing on immune medicine and minimal residual disease (MRD) diagnostics. The strong growth in its MRD business, particularly with clonoSEQ, aligns with a broader industry trend towards precision medicine and personalized diagnostics in oncology. The update to NCCN guidelines for CLL to include MRD-guided treatment duration signifies increasing clinical acceptance and integration of such advanced diagnostic tools into standard care, potentially expanding market opportunities for companies like Adaptive Biotechnologies.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased revenue, profitability, and raised guidance, potentially leading to increased share value.
• Employees: Continued growth and positive financial trajectory may ensure job security and potential for growth within the company.
• Customers (Patients/Clinicians): Increased adoption of clonoSEQ and NCCN guideline updates suggest improved access to and utility of advanced diagnostic tools for disease management.
• Biopharmaceutical Partners: Continued progress in Immune Medicine programs and MRD pharma regulatory milestones indicate ongoing collaboration opportunities.

Next Steps

• Host a conference call on November 5, 2025, at 4:30 PM Eastern Time to discuss Q3 2025 financial results and provide further outlook details.
• Continue efforts to develop, commercialize, and achieve market acceptance of current and planned products and services.
• Ongoing research and development efforts in both MRD and Immune Medicine programs.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q3 2025, marked by a 102% revenue increase and a significant shift from net loss to net income. The MRD business achieved a critical inflection point with profitability and cash flow positivity, coupled with raised revenue guidance and reduced expense forecasts. This indicates strong operational execution, market adoption of clonoSEQ, and effective cost management. While the Genentech agreement termination is noted, the core business strength and positive outlook suggest substantial upside potential for investors.

Keywords

Adaptive Biotechnologies, ADPT, Biotechnology, Financial Results, Q3 2025, MRD, Minimal Residual Disease, clonoSEQ, Immune Medicine, Earnings Report, Cancer Diagnostics, Biopharma